Secular Trends in the Management of Pediatric Graves' Disease: A 25-Year Cohort.

IF 3.8 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Noa Anchel, Naama Fisch-Shvalb, Michal Yakobovtich-Gavan, Ariel Tenenbaum, Liora Lazar, Moshe Phillip, Tal Oron
{"title":"Secular Trends in the Management of Pediatric Graves' Disease: A 25-Year Cohort.","authors":"Noa Anchel, Naama Fisch-Shvalb, Michal Yakobovtich-Gavan, Ariel Tenenbaum, Liora Lazar, Moshe Phillip, Tal Oron","doi":"10.1159/hrp/adaag001","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Over the past two decades, management of pediatric Graves' disease (GD) has shifted toward prolonged antithyroid drug therapy. Yet, longitudinal data describing how these changes have influenced long-term outcomes remain limited. This study examined secular trends in presentation, treatment strategies, and long-term outcomes of pediatric GD over a 25-year period at a tertiary center.</p><p><strong>Methods: </strong>A retrospective cohort study of children diagnosed with GD between 1999 and 2024. Outcomes included temporal changes in initial therapy, methimazole (MMI) dosing, definitive therapy (radioactive iodine ablation or thyroidectomy), remission and relapse rates, and treatment-related adverse events.</p><p><strong>Results: </strong>A total of 128 children (79.7% female), median age 13.8 years (IQR 10.0-15.6), median follow-up 6.0 years (IQR 3.3-10.4) were included in the study. Initial management shifted exclusively to MMI, with discontinuation of propylthiouracil after 2009 (p < 0.001). Median initial MMI dose declined progressively over the study period from 30 mg/day in 1999-2004 to 10 mg/day in 2015-2020 (p < 0.001 for the trend), with a parallel reduction in weight-adjusted dosing from 0.59 to 0.32 mg/kg/day (p < 0.001 for trend). Similarly, the use of RAI decreased steadily across calendar periods, from 55.6% in 1999-2004 to 9.8% in 2020-2024 (p < 0.001 for trend). Remission and remission with relapse rates did not differ significantly across calendar periods. Lower FT4 levels at diagnosis were marginally associated with remission (B = 0.41, SE = 0.22, p = 0.06). MMI-related Aes occurred in 20.3% of patients, with severe events in 1.6%.</p><p><strong>Conclusion: </strong>Over 25 years, pediatric GD management evolved toward lower dose, prolonged MMI therapy with a marked decline in definitive treatment. These secular changes were not associated with worsening remission or relapse rates, supporting the feasibility of a sustained conservative approach without evidence of inferior long-term outcomes.</p>","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":" ","pages":"1"},"PeriodicalIF":3.8000,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Research in Paediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/hrp/adaag001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Over the past two decades, management of pediatric Graves' disease (GD) has shifted toward prolonged antithyroid drug therapy. Yet, longitudinal data describing how these changes have influenced long-term outcomes remain limited. This study examined secular trends in presentation, treatment strategies, and long-term outcomes of pediatric GD over a 25-year period at a tertiary center.

Methods: A retrospective cohort study of children diagnosed with GD between 1999 and 2024. Outcomes included temporal changes in initial therapy, methimazole (MMI) dosing, definitive therapy (radioactive iodine ablation or thyroidectomy), remission and relapse rates, and treatment-related adverse events.

Results: A total of 128 children (79.7% female), median age 13.8 years (IQR 10.0-15.6), median follow-up 6.0 years (IQR 3.3-10.4) were included in the study. Initial management shifted exclusively to MMI, with discontinuation of propylthiouracil after 2009 (p < 0.001). Median initial MMI dose declined progressively over the study period from 30 mg/day in 1999-2004 to 10 mg/day in 2015-2020 (p < 0.001 for the trend), with a parallel reduction in weight-adjusted dosing from 0.59 to 0.32 mg/kg/day (p < 0.001 for trend). Similarly, the use of RAI decreased steadily across calendar periods, from 55.6% in 1999-2004 to 9.8% in 2020-2024 (p < 0.001 for trend). Remission and remission with relapse rates did not differ significantly across calendar periods. Lower FT4 levels at diagnosis were marginally associated with remission (B = 0.41, SE = 0.22, p = 0.06). MMI-related Aes occurred in 20.3% of patients, with severe events in 1.6%.

Conclusion: Over 25 years, pediatric GD management evolved toward lower dose, prolonged MMI therapy with a marked decline in definitive treatment. These secular changes were not associated with worsening remission or relapse rates, supporting the feasibility of a sustained conservative approach without evidence of inferior long-term outcomes.

儿童Graves病管理的长期趋势:一项25年队列研究
背景:在过去的二十年中,小儿Graves病(GD)的治疗已经转向长期抗甲状腺药物治疗。然而,描述这些变化如何影响长期结果的纵向数据仍然有限。目的:研究一个三级医疗中心25年来儿童GD的表现、治疗策略和长期结果的长期趋势。设计和背景:对1999年至2024年间诊断为GD的儿童进行回顾性队列研究。参与者:128名儿童(79.7%为女性),中位年龄13.8岁(IQR 10.0-15.6),中位随访6.0年(IQR 3.3-10.4)。主要结局指标:初始治疗的时间变化、甲巯咪唑(MMI)剂量、最终治疗放射性碘(RAI)消融或甲状腺切除术、缓解率和复发率以及治疗相关不良事件。结果:最初的治疗完全转向MMI, 2009年后停用丙基硫脲嘧啶(PTU) (P < 0.001)。在研究期间,初始MMI剂量中位数从1999-2004年的30 mg/天逐渐下降到2015-2020年的10 mg/天(趋势P < 0.001),体重调整剂量从0.59 mg/kg/天下降到0.32 mg/kg/天(趋势P < 0.001)。同样,RAI的使用在日历期间稳步下降,从1999-2004年的55.6%下降到2020-2024年的9.8%(趋势P < 0.001)。缓解和缓解伴复发率在日历期间无显著差异。诊断时较低的FT4水平与缓解无关(B=0.41, SE=0.22, P=0.06)。20.3%的患者发生mmi相关不良事件,1.6%的患者发生严重事件。结论:在过去的25年里,儿童GD管理朝着低剂量、延长MMI治疗的方向发展,最终治疗的比例明显下降。这些长期变化与恶化的缓解或复发率无关,支持持续保守方法的可行性,没有证据表明长期预后较差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hormone Research in Paediatrics
Hormone Research in Paediatrics ENDOCRINOLOGY & METABOLISM-PEDIATRICS
CiteScore
4.90
自引率
6.20%
发文量
88
审稿时长
4-8 weeks
期刊介绍: The mission of ''Hormone Research in Paediatrics'' is to improve the care of children with endocrine disorders by promoting basic and clinical knowledge. The journal facilitates the dissemination of information through original papers, mini reviews, clinical guidelines and papers on novel insights from clinical practice. Periodic editorials from outstanding paediatric endocrinologists address the main published novelties by critically reviewing the major strengths and weaknesses of the studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书